Basic information Reactions Safety Supplier Related

(-)-1,1'-BIS((2S,4S)-2,4-DIETHYLPHOSPHOTANO)FERROCENE

Basic information Reactions Safety Supplier Related

(-)-1,1'-BIS((2S,4S)-2,4-DIETHYLPHOSPHOTANO)FERROCENE Basic information

Product Name:
(-)-1,1'-BIS((2S,4S)-2,4-DIETHYLPHOSPHOTANO)FERROCENE
Synonyms:
  • (-)-1,1'-Bis[(2S,4S)-2,4-diethylphosphotano)ferrocene: 95% (S,S)-Et-FerroTANE
  • (-)-1,1'-Bis((2S,4S)-2,4-diethylphosphotano)ferrocene (S,S)-Et-FerroTANE
  • (S,S)-ET-FERROTANE(TM)
  • Bisdiethylphosphotanoferrocene
  • (-)-1,1'-Bis((2S,4S)-2,4-diethylphosphotano)ferrocene,min.95%(S,S)-Et-FerroTANE
  • (-)-1,1'-BIS((2S,4S)-2,4-DIETHYLPHOSPHONATO)FERROCENE,MIN.95%(S,S)-ET-FERROTANE
  • (-)-1,1'-Bis((2S,4S)-2,4-diethylphosphonato)ferrocene, min. 95% (S,S)-Et-FerroTANE(R)
  • (-)-1,1'-Bis((2S,4S)-2,4-diethylphosphonato)ferrocene, min. 95% (S,S)-Et-FerroTANE
CAS:
290347-66-9
MF:
C24H36FeP210*
MW:
442.34
Mol File:
290347-66-9.mol
More
Less

(-)-1,1'-BIS((2S,4S)-2,4-DIETHYLPHOSPHOTANO)FERROCENE Chemical Properties

Melting point:
76°C
alpha 
-660° (c 1, heptane)
form 
Powder
color 
yellow-orange
Sensitive 
air sensitive
More
Less

Safety Information

Risk Statements 
36/37/38
Safety Statements 
26-36/37/39
More
Less

(-)-1,1'-BIS((2S,4S)-2,4-DIETHYLPHOSPHOTANO)FERROCENE Usage And Synthesis

Reactions

Ligand for Ir-catalyzed [2+2+2] cycloaddition for enantioselective synthesis of silahelicenes. 2. Ligand for the preparation of (2,3-dihydrobenzofuran-3-yl)-acetic acid derivatives via Rh-catalyzed asymmetric hydrogenation. 

(-)-1,1'-BIS((2S,4S)-2,4-DIETHYLPHOSPHOTANO)FERROCENESupplier

J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
Meryer (Shanghai) Chemical Technology Co., Ltd.
Tel
021-61259108 18621169109
Email
market03@meryer.com
Shanghai Anyinuo Biomedical Technology Co., Ltd.
Tel
021-34625901
Email
420970979@qq.com
Beijing Jin Ming Biotechnology Co., Ltd.
Tel
010-60605840
Email
psaitong@jm-bio.com
PharmaBlock Sciences (Nanjing), Inc.
Tel
4000255188 13327728092
Email
gao_ning@pharmablock.com
More
Less